Physician

Chinyere Okeke, MD

According to 2025 Medicare claims, Chinyere Okeke, MD (NPI: 1255562880) practices family practice in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is CHINYERE OKEKE MD LTD (NPI: 1477980894; TIN: 463657029) and primary practice location at 89117-9198.

Okeke's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 145 traditional Medicare patients, billed 929 HCPCS/CPT codes, and received $69,202 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,800 prescription claims across 181 beneficiaries totaling $282,484 in drug costs, led by Ozempic (Semaglutide). DME data shows 36 claims. Open Payments data shows 24 records totaling $549. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $97,934 to $69,202. In contrast, Part D prescription costs have risen steadily, from $165,017 to $282,484. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $2,306 and ending at $3,578.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	216	1,193	$97,934
2016	258	1,291	$95,851
2017	304	1,894	$119,244
2018	336	1,726	$113,208
2019	295	1,695	$114,263
2020	226	1,376	$97,820
2021	184	1,119	$88,106
2022	164	977	$77,126
2023	154	946	$73,069
2024	145	929	$69,202

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	157	3,016	$165,017
2016	197	3,630	$244,106
2017	222	3,118	$204,607
2018	205	2,897	$217,431
2019	205	2,867	$214,765
2020	195	2,867	$195,707
2021	183	2,768	$230,707
2022	173	2,660	$299,806
2023	169	2,439	$297,174
2024	181	2,800	$282,484

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	72	$2,226
2016	26	98	$2,638
2017	13	149	$5,033
2018	14	169	$6,093
2019	N/R	103	$3,845
2020	N/R	23	$6,639
2021	N/R	57	$7,001
2022	N/R	72	$7,392
2023	N/R	N/R	N/R
2024	N/R	36	$527

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	25	28	$132
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	554	$86
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	20	20	$85
90833	Psychotherapy with evaluation and management visit, 30 minutes	65	303	$49

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	45	2,092	$64,886
Eliquis	Apixaban	20	1,260	$24,681
Jardiance	Empagliflozin	20	1,320	$24,568
Mounjaro	Tirzepatide	12	392	$14,760
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	36	1,039	$7,886

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	12	$294
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	N	N/R	11	$175
E0570	Nebulizer, with compressor	Y	N/R	13	$58

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	24	$549	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chinyere Okeke, MD?

Tedicare shows public-source Medicare data for Chinyere Okeke, MD (NPI 1255562880), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chinyere Okeke, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chinyere Okeke, MD?

Chinyere Okeke, MD is linked to CHINYERE OKEKE MD LTD (billing NPI 1477980894) in the available physician profile data.

Does Chinyere Okeke, MD have Open Payments data?

Chinyere Okeke, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.